PharmaMar moves ahead with NDA for ZepsyreThe FDA has given the go-ahead to PharmaMars proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung … more ➔
Swedish researchers find new pain organResearchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts. more ➔
Researchers unravel potential cancer targe...British researchers have found out what’s going wrong with chromosome segregation in some cancers. more ➔
Pharming licenses orphan drug from Novarti...Pharming NV has paid €17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS more ➔
New stem cell population may help repair t... Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future. more ➔
Bayer bags iPSC specialist BlueRock Therap...Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics. more ➔
Liquid biopsy identifies residual breast c...Using a platform tailored to patients specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients. more ➔
Novo Holdings puts $72m in LanzatechNovo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the companys sustainable fuels and chemicals platform more ➔
Google maps for tumours and organsGerman researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy. more ➔
Transgenes licenced oncolytic virus fail... SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint … more ➔
